Bläuenstein P - Search Results

1

Non-invasive assessment of tumour cell proliferation with positron emission tomography and [76Br]bromodeoxyuridine.

Böni R, Bläuenstein P, Dummer R, von Schulthess GK, Schubiger PA, Steinert HC. Böni R, et al. Among authors: blauenstein p. Melanoma Res. 1999 Dec;9(6):569-73. doi: 10.1097/00008390-199912000-00005. Melanoma Res. 1999. PMID: 10661767

2

[76Br]Bromodeoxyuridine, a potential tracer for the measurement of cell proliferation by positron emission tomography, in vitro and in vivo studies in mice.

Ryser JE, Bläuenstein P, Rémy N, Weinreich R, Hasler PH, Novak-Hofer I, Schubiger PA. Ryser JE, et al. Among authors: blauenstein p. Nucl Med Biol. 1999 Aug;26(6):673-9. doi: 10.1016/s0969-8051(99)00042-6. Nucl Med Biol. 1999. PMID: 10587106

3

Monoamine oxidase B single-photon emission tomography with [123I]Ro 43-0463: imaging in volunteers and patients with temporal lobe epilepsy.

Buck A, Frey LD, Bläuenstein P, Krämer G, Siegel A, Weber B, Schubiger PA, Wieser HG. Buck A, et al. Among authors: blauenstein p. Eur J Nucl Med. 1998 May;25(5):464-70. doi: 10.1007/s002590050245. Eur J Nucl Med. 1998. PMID: 9575241

4

Measurement of the extracellular space in brain tumors using 76Br-bromide and PET.

Bruehlmeier M, Roelcke U, Bläuenstein P, Missimer J, Schubiger PA, Locher JT, Pellikka R, Ametamey SM. Bruehlmeier M, et al. Among authors: blauenstein p. J Nucl Med. 2003 Aug;44(8):1210-8. J Nucl Med. 2003. PMID: 12902409 Free article. Clinical Trial.

5

Regulation of the cell surface expression of a nonspecific cross-reacting antigen variant during differentiation of HL-60 cells.

Novak-Hofer I, Bläuenstein P, Schubiger PA. Novak-Hofer I, et al. Among authors: blauenstein p. Cancer Res. 1990 Dec 1;50(23):7437-43. Cancer Res. 1990. PMID: 2174725

6

Immunoscintigraphic localization of inflammatory lesions: clinical experience.

Seybold K, Locher JT, Coosemans C, Andres RY, Schubiger PA, Bläuenstein P. Seybold K, et al. Among authors: blauenstein p. Eur J Nucl Med. 1988;13(11):587-93. doi: 10.1007/BF02574774. Eur J Nucl Med. 1988. PMID: 3258240

7

Reinvestigation of a physiological eluate of the 52Fe/52mMn generator.

Bläuenstein P, Pellikka R, Schubiger PA. Bläuenstein P, et al. Appl Radiat Isot. 1997 Aug;48(8):1097-101. doi: 10.1016/s0969-8043(97)00106-1. Appl Radiat Isot. 1997. PMID: 9394439

8

In vivo properties of N-(2-aminoethyl)-5-halogeno-2-pyridinecarboxamide 18F- and 123I-labelled reversible inhibitors of monoamine oxidase B.

Bläuenstein P, Rémy N, Buck A, Ametamey S, Häberli M, Schubiger PA. Bläuenstein P, et al. Nucl Med Biol. 1998 Jan;25(1):47-52. doi: 10.1016/s0969-8051(97)00143-1. Nucl Med Biol. 1998. PMID: 9466361

9

In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors.

Grünberg J, Novak-Hofer I, Honer M, Zimmermann K, Knogler K, Bläuenstein P, Ametamey S, Maecke HR, Schubiger PA. Grünberg J, et al. Among authors: blauenstein p. Clin Cancer Res. 2005 Jul 15;11(14):5112-20. doi: 10.1158/1078-0432.CCR-05-0227. Clin Cancer Res. 2005. PMID: 16033825

10

A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours.

García-Garayoa E, Bläuenstein P, Blanc A, Maes V, Tourwé D, Schubiger PA. García-Garayoa E, et al. Among authors: blauenstein p. Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):37-47. doi: 10.1007/s00259-008-0894-y. Epub 2008 Aug 9. Eur J Nucl Med Mol Imaging. 2009. PMID: 18690434

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters